[g10r]

It's not bad per se, it's just how it works. Like pretty much everything in life the outcome is dependent on the people involved. You're not getting the potential for more upside without the introduction of more risk.

Chamath is currently leading four biotech SPACS: DNAA, DNAB, DNAC and DNAD, each with a stated target, neurology, oncology, organs & immunology. Anyone looking to invest in the SPAC today should consider the likelihood of this happening, the potential targets, and the sponsors history.

Or you can wait for an announcement around a proposed merger, even up to the day the official stock starts being traded.

Again, just depends on risk tolerance. It's nice to least have the option to take part in these deals.